Skip to content

Study · Animal study (in vivo) · rat · 2021

6 results

BPC 157 Therapy and the Permanent Occlusion of the Superior Sagittal Sinus in Rat: Vascular Recruitment.

Gojkovic S, Krezic I, Vranes H, Zizek H, Drmic D, Horvat Pavlov K, Petrovic A, Batelja Vuletic L, Milavic M, Sikiric S, Stilinovic I, Samara M and 7 more

Show all authors

Knezevic M, Barisic I, Sjekavica I, Lovric E, Skrtic A, Seiwerth S, Sikiric P

Biomedicines28 Jun 2021Cited by 35 (Europe PMC)

Summary

We show the complex syndrome of the occluded superior sagittal sinus, brain swelling and lesions and multiple peripheral organs lesions in rat. Recovery goes centrally and peripherally, with the stable gastric pentadecapeptide BPC 157, which alleviated peripheral vascular occlusion disturbances, rapidly activating alternative bypassing pathways. Assessments were gross recording, venography, ECG, pressure, microscopy, biochemistry. The increased pressure in the superior sagittal sinus, portal and caval hypertension, aortal hypotension, arterial and venous thrombosis, severe brain swelling and lesions (cortex (cerebral, cerebellar), hypothalamus/thalamus, hippocampus), particular veins (azygos, superior mesenteric, inferior caval) dysfunction, heart dysfunction, lung congestion as acute respiratory distress syndrome, kidney disturbances, liver failure, and hemorrhagic lesions in gastrointestinal tract were all assessed. Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally, intragastrically, or topically to the swollen brain at 1 min ligation-time, or at 15 min, 24 h and 48 h ligation-time. BPC 157 therapy rapidly attenuates the brain swelling, rapidly eliminates the increased pressure in the ligated superior sagittal sinus and the severe portal and caval hypertension and aortal hypotension, and rapidly recruits collateral vessels, centrally ((para)sagittal venous collateral circulation) and peripherally (left superior caval vein azygos vein-inferior caval vein). In conclusion, as shown by all assessments, BPC 157 acts against the permanent occlusion of the superior sagittal sinus and syndrome (i.e., brain, heart, lung, liver, kidney, gastrointestinal lesions, thrombosis), given at 1 min, 15 min, 24 h or 48 h ligation-time. BPC 157 therapy rapidly overwhelms the permanent occlusion of the superior sagittal sinus in rat.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with permanent superior sagittal sinus occlusion, BPC‑157 rapidly attenuated brain swelling.

    In plain wordsIn rats with a blocked brain vein, BPC‑157 quickly reduced brain swelling.

    Peptide
    BPC-157
    Outcome
    DecreaseBrain swelling
    Study

    ratn: not reported in source

    Permanent occlusion of the superior sagittal sinus
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitoneal, intragastric, or topical to the swollen brainAs given in this study (rat).

    Source sentences

    Summary
    rapidly attenuates the brain swelling
    2 context sentences
    Summary · context
    We show the complex syndrome of the occluded superior sagittal sinus, brain swelling and lesions and multiple peripheral organs lesions in rat.
    Summary · context
    Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally, intragastrically, or topically to the swollen brain at 1 min ligation-time, or at 15 min, 24 h and 48 h ligation-time.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with permanent superior sagittal sinus occlusion, BPC‑157 rapidly eliminated the increased pressure in the ligated sinus.

    In plain wordsIn rats with a blocked brain vein, BPC‑157 quickly removed the raised pressure in that vein.

    Peptide
    BPC-157
    Outcome
    DecreasePressure in the ligated superior sagittal sinus
    Study

    ratn: not reported in source

    Permanent occlusion of the superior sagittal sinus
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitoneal, intragastric, or topical to the swollen brainAs given in this study (rat).

    Source sentences

    Summary
    rapidly eliminates the increased pressure in the ligated superior sagittal sinus
    2 context sentences
    Summary · context
    We show the complex syndrome of the occluded superior sagittal sinus, brain swelling and lesions and multiple peripheral organs lesions in rat.
    Summary · context
    Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally, intragastrically, or topically to the swollen brain at 1 min ligation-time, or at 15 min, 24 h and 48 h ligation-time.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with permanent superior sagittal sinus occlusion, BPC‑157 eliminated severe portal and caval hypertension.

    In plain wordsIn rats with a blocked brain vein, BPC‑157 removed severe high pressure in two large abdominal veins.

    Peptide
    BPC-157
    Outcome
    DecreasePortal and caval hypertension
    Study

    ratn: not reported in source

    Permanent occlusion of the superior sagittal sinus
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitoneal, intragastric, or topical to the swollen brainAs given in this study (rat).

    Source sentences

    Summary
    the severe portal and caval hypertension and aortal hypotension
    2 context sentences
    Summary · context
    We show the complex syndrome of the occluded superior sagittal sinus, brain swelling and lesions and multiple peripheral organs lesions in rat.
    Summary · context
    Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally, intragastrically, or topically to the swollen brain at 1 min ligation-time, or at 15 min, 24 h and 48 h ligation-time.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with permanent superior sagittal sinus occlusion, BPC‑157 eliminated aortal hypotension.

    In plain wordsIn rats with a blocked brain vein, BPC‑157 removed the low aortic pressure.

    Peptide
    BPC-157
    Outcome
    IncreaseAortal hypotension
    Study

    ratn: not reported in source

    Permanent occlusion of the superior sagittal sinus
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitoneal, intragastric, or topical to the swollen brainAs given in this study (rat).

    Source sentences

    Summary
    the severe portal and caval hypertension and aortal hypotension
    2 context sentences
    Summary · context
    We show the complex syndrome of the occluded superior sagittal sinus, brain swelling and lesions and multiple peripheral organs lesions in rat.
    Summary · context
    Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally, intragastrically, or topically to the swollen brain at 1 min ligation-time, or at 15 min, 24 h and 48 h ligation-time.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with permanent superior sagittal sinus occlusion, BPC‑157 rapidly recruited collateral vessels centrally and peripherally.

    In plain wordsIn rats with a blocked brain vein, BPC‑157 quickly opened extra blood vessels to carry the flow.

    Peptide
    BPC-157
    Outcome
    IncreaseCollateral vessel recruitment
    Study

    ratn: not reported in source

    Permanent occlusion of the superior sagittal sinus
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitoneal, intragastric, or topical to the swollen brainAs given in this study (rat).

    Source sentences

    Summary
    rapidly recruits collateral vessels, centrally ((para)sagittal venous collateral circulation) and peripherally (left superior caval vein azygos vein-inferior caval vein).
    2 context sentences
    Summary · context
    We show the complex syndrome of the occluded superior sagittal sinus, brain swelling and lesions and multiple peripheral organs lesions in rat.
    Summary · context
    Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally, intragastrically, or topically to the swollen brain at 1 min ligation-time, or at 15 min, 24 h and 48 h ligation-time.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with permanent superior sagittal sinus occlusion, BPC‑157 acted against the occlusion syndrome when given at 1 min, 15 min, 24 h or 48 h ligation-time.

    In plain wordsIn rats with a blocked brain vein, BPC‑157 reduced organ damage and clots, even when given up to 48 hours later.

    Peptide
    BPC-157
    Outcome
    DecreaseSyndrome of brain, heart, lung, liver, kidney and gastrointestinal lesions and thrombosis
    Study

    ratn: not reported in source

    Permanent occlusion of the superior sagittal sinus
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitoneal, intragastric, or topical to the swollen brainAs given in this study (rat).

    Source sentences

    Summary
    In conclusion, as shown by all assessments, BPC 157 acts against the permanent occlusion of the superior sagittal sinus and syndrome (i.e., brain, heart, lung, liver, kidney, gastrointestinal lesions, thrombosis), given at 1 min, 15 min, 24 h or 48 h ligation-time.
    2 context sentences
    Summary · context
    We show the complex syndrome of the occluded superior sagittal sinus, brain swelling and lesions and multiple peripheral organs lesions in rat.
    Summary · context
    Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally, intragastrically, or topically to the swollen brain at 1 min ligation-time, or at 15 min, 24 h and 48 h ligation-time.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.